blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3458040

EP3458040 - COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH NMDA RECEPTOR ANTAGONIST [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.12.2021
Database last updated on 31.03.2026
FormerThe patent has been granted
Status updated on  25.12.2020
FormerGrant of patent is intended
Status updated on  20.10.2020
FormerExamination is in progress
Status updated on  16.09.2020
FormerGrant of patent is intended
Status updated on  10.08.2020
FormerExamination is in progress
Status updated on  22.10.2019
FormerRequest for examination was made
Status updated on  22.02.2019
FormerThe international publication has been made
Status updated on  25.11.2017
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Suven Life Sciences Limited
5th Floor Serene Chambers
Road No. 5
Off Avenue 7
Banjara Hills
Hyderabad, Telangana 500034 / IN
[2019/13]
Inventor(s)01 / NIROGI, Ramakrishna
Serene Chambers
Road-5
Avenue 7
Banjara Hills
Hyderabad Telangana 500034 / IN
02 / SHINDE, Anil Karbhari
Serene Chambers
Road-5
Avenue 7
Banjara Hills
Hyderabad Telangana 500034 / IN
03 / JAYARAJAN, Pradeep
Serene Chambers
Road-5
Avenue 7
Banjara Hills
Hyderabad Telangana 500034 / IN
04 / BHYRAPUNENI, Gopinadh
Serene Chambers
Road-5
Avenue 7
Banjara Hills
Hyderabad Telangana 500034 / IN
05 / KAMBHAMPATI, Ramasastri
Serene Chambers
Road-5
Avenue 7
Banjara Hills
Hyderabad Telangana 500034 / IN
06 / JASTI, Venkateswarlu
Serene Chambers
Road-5
Avenue 7
Banjara Hills
Hyderabad Telangana 500034 / IN
 [2019/13]
Representative(s)HGF
HGF Limited
4th Floor, 1 City Square
Leeds LS1 2ES / GB
[N/P]
Former [2021/04]HGF
1 City Walk
Leeds LS11 9DX / GB
Former [2019/13]HGF Limited
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date16766623.903.08.2016
[2019/13]
WO2016IB54674
Priority number, dateIN20164101720318.05.2016         Original published format: IN201641017203
[2019/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017199072
Date:23.11.2017
Language:EN
[2017/47]
Type: A1 Application with search report 
No.:EP3458040
Date:27.03.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 23.11.2017 takes the place of the publication of the European patent application.
[2019/13]
Type: B1 Patent specification 
No.:EP3458040
Date:27.01.2021
Language:EN
[2021/04]
Search report(s)International search report - published on:EP23.11.2017
ClassificationIPC:A61K31/13, A61K31/496, A61P25/28, A61P25/16, A61P25/18
[2020/37]
CPC:
A61K31/496 (EP,EA,IL,KR,US); A61K31/13 (EP,EA,IL,KR,US); A61P25/00 (EP);
A61P25/16 (EP,IL,KR); A61P25/18 (EP,IL,KR); A61P25/28 (EP,IL,KR);
A61P43/00 (EP); A61K2300/00 (IL,KR) (-)
C-Set:
A61K31/13, A61K2300/00 (EP,US);
A61K31/496, A61K2300/00 (US,EP)
Former IPC [2019/13]A61K31/13, A61K31/496, A61P25/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/13]
Extension statesBA03.12.2018
ME03.12.2018
Validation statesMA03.12.2018
MD03.12.2018
TitleGerman:KOMBINATION AUS REINEN 5-HT6-REZEPTORANTAGONISTEN MIT NMDA-REZEPTORANTAGONISTEN[2019/13]
English:COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH NMDA RECEPTOR ANTAGONIST[2019/13]
French:COMBINAISON D'ANTAGONISTES PURS DES RÉCEPTEURS 5-HT6 ET D'UN ANTAGONISTE DES RÉCEPTEURS NMDA[2019/13]
Entry into regional phase03.12.2018National basic fee paid 
03.12.2018Designation fee(s) paid 
03.12.2018Examination fee paid 
Examination procedure27.11.2017Request for preliminary examination filed
International Preliminary Examining Authority: EP
03.12.2018Examination requested  [2019/13]
03.12.2018Date on which the examining division has become responsible
17.06.2019Amendment by applicant (claims and/or description)
25.10.2019Despatch of a communication from the examining division (Time limit: M04)
14.01.2020Reply to a communication from the examining division
11.08.2020Communication of intention to grant the patent
16.09.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
21.10.2020Communication of intention to grant the patent
21.12.2020Fee for grant paid
21.12.2020Fee for publishing/printing paid
21.12.2020Receipt of the translation of the claim(s)
Opposition(s)28.10.2021No opposition filed within time limit [2022/01]
Fees paidRenewal fee
03.12.2018Renewal fee patent year 03
05.07.2019Renewal fee patent year 04
06.08.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL27.01.2021
AT27.01.2021
CY27.01.2021
CZ27.01.2021
EE27.01.2021
ES27.01.2021
FI27.01.2021
IT27.01.2021
LT27.01.2021
LV27.01.2021
MK27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
TR27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
[2026/04]
Former [2024/22]AL27.01.2021
AT27.01.2021
CY27.01.2021
CZ27.01.2021
EE27.01.2021
ES27.01.2021
FI27.01.2021
IT27.01.2021
LT27.01.2021
LV27.01.2021
MK27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
Former [2023/30]AL27.01.2021
AT27.01.2021
CY27.01.2021
CZ27.01.2021
EE27.01.2021
ES27.01.2021
FI27.01.2021
IT27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
Former [2022/23]AL27.01.2021
AT27.01.2021
CZ27.01.2021
EE27.01.2021
ES27.01.2021
FI27.01.2021
IT27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
Former [2022/13]AL27.01.2021
AT27.01.2021
CZ27.01.2021
EE27.01.2021
ES27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
PT27.05.2021
Former [2022/10]AL27.01.2021
AT27.01.2021
CZ27.01.2021
EE27.01.2021
ES27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
PT27.05.2021
Former [2022/08]AL27.01.2021
AT27.01.2021
CZ27.01.2021
EE27.01.2021
ES27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
Former [2022/07]AL27.01.2021
AT27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
Former [2021/50]AT27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
Former [2021/48]AT27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RS27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
Former [2021/46]AT27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RS27.01.2021
SM27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
Former [2021/42]AT27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RS27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
IS27.05.2021
PT27.05.2021
Former [2021/39]AT27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RS27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/37]AT27.01.2021
FI27.01.2021
LT27.01.2021
LV27.01.2021
RS27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/36]FI27.01.2021
LT27.01.2021
BG27.04.2021
NO27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/33]FI27.01.2021
LT27.01.2021
NO27.04.2021
PT27.05.2021
Cited inInternational search[Y] EP1902733  (ESTEVE LABOR DR et al.)
 [YD] WO2015083179  (SUVEN LIFE SCIENCES LTD et al.)
 [Y] WO2004048330  (SUVEN LIFE SCIENCES LTD et al.)
 [XY]   JAYARAJAN PRADEEP ET AL: "5-ht6antagonist SUVN-502 potentiates the procognitive and neurochemical effects of donepezil and memantine", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, vol. 11, no. 7, 1 July 2015 (2015-07-01), XP029353767, ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2015.06.517

DOI:   http://dx.doi.org/10.1016/j.jalz.2015.06.517
 [Y]   RENNY ABRAHAM ET AL: "Role of glutamate and advantages of combining memantine with a 5HT6 ligand in a model of depression", PHARMACOLOGICAL REPORTS, vol. 66, no. 3, 1 June 2014 (2014-06-01), PL, pages 394 - 398, XP055337146, ISSN: 1734-1140, DOI: 10.1016/j.pharep.2013.10.007

DOI:   http://dx.doi.org/10.1016/j.pharep.2013.10.007
 [Y]   NIROGI RAMAKRISHNA: "SUVN-502: A potent and selective 5-HT6 antagonist, potential drug for the treatment of Alzheimer's disease", ALZHEIMER AND DEMENTIA; THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION, 1 July 2011 (2011-07-01), pages S659, XP055335504, Retrieved from the Internet [retrieved on 20170116]

DOI:   http://dx.doi.org/10.1016/j.jalz.2011.05.1895
by applicantUS7875605
 WO2008034815
 WO2015083179
   BRITISH JOURNAL OF PHARMACOLOGY, vol. 130, 2000, pages 23 - 26
   THE COCHRANE LIBRARY, vol. 4, 2004, pages 1 - 68
   ARCHIVES OF NEUROLOGY, vol. 68, no. 8, 2011, pages 991 - 998
   MOLECULAR PHARMACOLOGY, vol. 43, 1993, pages 320 - 327
   BRITISH JOURNAL OF PHARMACOLOGY, vol. 126, 1999, pages 1537 - 1542
   CNS & NEUROLOGICAL DISORDERS - DRUG TARGETS, vol. 3, 2004, pages 59 - 79
   MOLECULAR BRAIN RESEARCH, vol. 90, 2001, pages 110 - 117
   BRITISH JOURNAL OF PHARMACOLOGY, vol. 148, 2006, pages 1133 - 1143
   METHODS IN MOLECULAR BIOLOGY, vol. 190, 2002, pages 31 - 49
   BEHAVIOURAL BRAIN RESEARCH, vol. 31, 1988, pages 47 - 59
   PAXINOS G.; WATSON C.: "Rat brain in stereotaxic coordinates", 2004, ACADEMIC PRESS
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.